Product category |
|
Therapeutic indication |
|
Dosing |
|
Efficacy |
|
Key features |
|
Challenges |
|
Status |
- Approved by US FDA July 2018 and by Australian TGA September 2018
- Approved in first malaria-endemic country (Brazil) in October 2019, in Thailand in December 2019 and in Peru in January 2021
- Under review in 4 endemic countries + additional 2 under ASEAN joint assessment procedure review
|
Next milestone |
Pharmacokinetic results expected for the INSPECTOR study, assessing safety and efficacy of TQ in combination with DHA-PQP Start of feasibility study in Brazil and in Thailand, in conjunction with quantitative G6PD testing
|
MMV Project Director |
|